MONUROL Drug Patent Profile

When do Monurol patents expire, and what generic alternatives are available?

Monurol is a drug marketed by Zambon Spa and is included in one NDA.

The generic ingredient in MONUROL is fosfomycin tromethamine. There are six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the fosfomycin tromethamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Monurol

A generic version of MONUROL was approved as fosfomycin tromethamine by XIROMED on October 6^th, 2020.

Summary for MONUROL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	51
Clinical Trials:	4
Patent Applications:	664
Drug Prices:	Drug price information for MONUROL
What excipients (inactive ingredients) are in MONUROL?	MONUROL excipients list
DailyMed Link:	MONUROL at DailyMed

See drug prices for MONUROL

Recent Clinical Trials for MONUROL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jordi Gol i Gurina Foundation	Phase 4
Balearic Islands Health Service (Ibsalut)	Phase 4
Instituto de Investigación Sanitaria Aragón	Phase 4

See all MONUROL clinical trials

US Patents and Regulatory Information for MONUROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zambon Spa	MONUROL	fosfomycin tromethamine	FOR SOLUTION;ORAL	050717-001	Dec 19, 1996		DISCN	Yes	No

Market Dynamics and Financial Trajectory for Monurol (Fosfomycin Tromethamine)

Last updated: March 16, 2026

What is the Current Market Position of Monurol?

Monurol (fosfomycin tromethamine) is an antibiotic approved by the FDA for uncomplicated urinary tract infections (UTIs). It acts by inhibiting bacterial cell wall synthesis and is administered as a single-dose oral treatment. Since its initial approval in 1996, Monurol has maintained niche status primarily within the US and select international markets. Its revenue generation remains limited relative to broader antibiotics portfolios but shows emerging growth potential.

Fundamentally, Monurol's market share is constrained by several factors:

• Competition from established antibiotics like nitrofurantoin, trimethoprim-sulfamethoxazole, and fluoroquinolones.
• Increasing antibiotic resistance in common UTI pathogens.
• Limited indications confined to uncomplicated cystitis.
• The absence of injectable formulations restricts use in complicated cases.

What Are the Market Drivers and Barriers?

Drivers:

• Rising antibiotic resistance: Fosfomycin retains activity against multidrug-resistant bacteria, including ESBL-producing E. coli and carbapenemase-producing strains.
• Single-dose convenience: Favors patient compliance and outpatient treatment.
• Regulatory approval in multiple regions: Expanding indications can boost usage.
• Emerging resistance to first-line antibiotics: May shift prescribing patterns towards fosfomycin-based treatments.

Barriers:

• Limited awareness: Many clinicians favor traditional antibiotics.
• Pricing competition: Generic versions exist, exerting downward pressure on margins.
• Narrow spectrum: Efficacy limited to uncomplicated cystitis.
• Limited brand promotion: As an older drug, Monurol's marketing often underfunded compared to newer agents.

What Is the Financial Trajectory?

Historical Revenue and Sales Trends

Year	U.S. Sales (USD millions)	Global Sales (USD millions)	Notes
2015	10	12	Stabilized from earlier years
2018	8	10	Slight decline amid generic entry
2021	15	18	Renewed interest in resistant infections

Note: These figures research estimates based on market reports and payer data.

Revenue Drivers:

• Increased prescribing for resistant UTIs: As resistance grows, fosfomycin prescriptions see incremental growth.
• New international approvals: Emerging markets could contribute 10-15% annual growth if marketed effectively, subject to regulatory timelines.
• Expansion indications: Off-label use in other infections or resistant pathogens could supplement revenue streams.

Key Financial Assessments:

• Monurol's profit margins are challenged by generic competition, which has stabilized prices at USD 30–USD 50 per treatment course.
• The current global market estimate is roughly USD 30 million annually, primarily in the US.
• Market growth CAGR projected at approximately 4–6% over the next five years, driven by resistance trends and expanding antibiotics stewardship.

Future Outlook:

• Potential for growth exists if new formulations, indications, or combinations are approved.
• Patent expirations in some regions may introduce generics, pressure margins but increased volume.
• R&D investments targeting resistant infections could help reposition Monurol within broader antimicrobial stewardship programs.

How Do Market Dynamics Compare Globally?

Region	Market Size (USD Millions)	Key Initiatives	Challenges
North America	20	Increased resistance, stewardship programs	Competition, low prescribing rates
Europe	5	Limited approvals, cost containment policies	Strict regulation, generic prevalence
Asia-Pacific	3–4	Expanding antimicrobial use, regulatory variations	Variable drug approval standards
Latin America	1–2	Growing healthcare access, resistance concerns	Market access, regulatory hurdles

Summarizing Market Trends

• The UTI antibiotic market is mature, with Monurol occupying a niche within resistant infection management.
• Growth is incremental, driven by resistance trends and international expansion.
• Existing competition constrains pricing and revenue growth rates.
• Competition from newer agents with broader indications could threaten Monurol’s position if not supplemented with strategic positioning.

Key Takeaways

• Monurol's global sales are approximately USD 30–35 million annually, with growth driven predominantly by resistance-driven prescribing.
• Its market faces ongoing competition from generics and alternative antibiotics, with limited scope beyond uncomplicated cystitis.
• Resistance dynamics and stewardship policies could expand Monurol’s use, especially for multidrug-resistant infections.
• International expansion and indication extensions are essential to unlock future revenue potential.
• Market growth projections suggest a 4–6% CAGR over the next five years, contingent on resistance trends and regulatory developments.

FAQs

1. What are the primary competitors to Monurol?
   Generic nitrofurantoin, trimethoprim-sulfamethoxazole, and fluoroquinolones like ciprofloxacin.

2. Is Monurol approved outside the US?
   Yes. It is approved in Europe, Japan, and several other regions, though indications and market penetration vary.

3. What impact does antibiotic resistance have on Monurol?
   Resistance reduces the efficacy of traditional drugs, boosting fosfomycin as a viable alternative for resistant UTIs.

4. Are there recent regulatory changes affecting Monurol?
   New imports and approvals may be underway in emerging markets, but the core indication remains unchanged internationally.

5. What are the prospects for Monurol in combination therapies?
   Currently limited, but research into synergistic use with other antibiotics may create new usage pathways.

---

References

[1] MarketResearch.com. (2022). Global Antibiotic Market Analysis.
[2] FDA. (2023). Fosfomycin Tromethamine (Monurol) Prescribing Information.
[3] European Medicines Agency. (2022). Approval Records for Fosfomycin.
[4] GlobalData Healthcare. (2022). Antibiotics Market Forecasts.
[5] Resistance Map. (2023). Global Antibiotic Resistance Data.